Erythrocyte Complement Receptor 1 and Alzheimer Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by CHU de Reims.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
CHU de Reims Identifier:
First received: March 26, 2012
Last updated: March 27, 2012
Last verified: March 2012
Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.

Condition Intervention
Alzheimer Disease
Other: CR1 impact

Study Type: Interventional
Study Design: Primary Purpose: Screening

Resource links provided by NLM:

Further study details as provided by CHU de Reims:

Estimated Enrollment: 200
Study Start Date: February 2012

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects

Exclusion Criteria:

  • diseases modifying CR1 physiology
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01565434

Contact: Rachid MAHMOUDI, MD

CHU de REIMS Recruiting
Reims, France, 51092
Contact: Rachid MAHMOUDI, MD   
Principal Investigator: Rachid MAHMOUDI, MD         
Sponsors and Collaborators
CHU de Reims
  More Information

Responsible Party: CHU de Reims Identifier: NCT01565434     History of Changes
Other Study ID Numbers: REIMS-AOL2011-01 
Study First Received: March 26, 2012
Last Updated: March 27, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Mental Disorders
Nervous System Diseases
Neurocognitive Disorders
Neurodegenerative Diseases
Tauopathies processed this record on May 25, 2016